Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2002

01-05-2002 | Notas Clínicas

Deletion 6q and +X in one primary central nervous system lymphoma (PCNSL) arising in a patient without immune defects

Authors: María Josefa Bello González, José María de Campos Gutiérrez, María Elena Kusak Lambea, José Luis Sarasa Corral, Juan Antonio Rey Herranz

Published in: Clinical and Translational Oncology | Issue 4/2002

Login to get access
Metadata
Title
Deletion 6q and +X in one primary central nervous system lymphoma (PCNSL) arising in a patient without immune defects
Authors
María Josefa Bello González
José María de Campos Gutiérrez
María Elena Kusak Lambea
José Luis Sarasa Corral
Juan Antonio Rey Herranz
Publication date
01-05-2002
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 4/2002
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/BF02717678

Other articles of this Issue 4/2002

Clinical and Translational Oncology 4/2002 Go to the issue

Sección docente

Radiotherapy and tumour hypoxia

Announcement

Información

Originales

Angiosarcoma de la mama: informe de 5 casos

Correspondencia

Cisplatin-5-fluorouracil-leucovorin (PFL) as neoadyuvant therapy in patients with locally advanced squamous cell carcinoma of the head and neck. Results after long-term follow up (réplica)

Editorial

Multidrug transporters in cancer resistance

Notas clínicas

Pancreatitis aguda inducida por L-asparraginasa
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits